Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. METHODS: We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years. Physicians were permitted to adjust other medications, including antihyperglycemic agents. The primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke. RESULTS: A primary end-point event occurred in 613 patients in the saxagliptin group and in 609 patients in the placebo group (7.3% and 7.2%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio with saxagliptin, 1.00; 95% confidence interval [CI], 0.89 to 1.12; P=0.99 for superiority; P<0.001 for noninferiority); the results were similar in the "on-treatment" analysis (hazard ratio, 1.03; 95% CI, 0.91 to 1.17). The major secondary end point of a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or heart failure occurred in 1059 patients in the saxagliptin group and in 1034 patients in the placebo group (12.8% and 12.4%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio, 1.02; 95% CI, 0.94 to 1.11; P=0.66). More patients in the saxagliptin group than in the placebo group were hospitalized for heart failure (3.5% vs. 2.8%; hazard ratio, 1.27; 95% CI, 1.07 to 1.51; P=0.007). Rates of adjudicated cases of acute and chronic pancreatitis were similar in the two groups (acute pancreatitis, 0.3% in the saxagliptin group and 0.2% in the placebo group; chronic pancreatitis, <0.1% and 0.1% in the two groups, respectively). CONCLUSIONS: DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes. (Funded by AstraZeneca and Bristol-Myers Squibb; SAVOR-TIMI 53 ClinicalTrials.gov number, NCT01107886.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Trials of HF outcomes with dapagliflozin and empagliflozin, enrolling up to 50% of participants with type 2 diabetes, report reduction in cardiovascular death and improvement of HF among patients with HF with reduced ejection fraction and HF with preserved ejection fraction, respectively, independent of diabetes status, compared with placebo.66–69,88”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [69]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 4 trials to date, the DPP4 inhibitors have been shown to be neutral in terms of cardiovascular outcomes.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [186]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of SAVOR-TIMI 53 (NCT01107886) and EXAMINE (NCT00968708) were recently released and showed no increased risk of cardiovascular events with the DPP-4 inhibitors saxagliptin96 and alogliptin97, respectively.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [19]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Self-citationThe Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Cited by
Items 601–700 of 1,020
Marlet, I. R., Ölmestig, J. N. E., Vilsbøll, T., Rungby, J., & Kruuse, C. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12974 · Cited by 61
Seong, J.-M., Choi, N., Shin, J., Chang, Y., Kim, Y.-J., Lee, J., Kim, J. Y., & Park, B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124287 · Cited by 61
Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
Smith, R. J., Goldfine, A. B., & Hiatt, W. R. (2016) · Diabetes Care · doi:10.2337/dc15-2237 · Cited by 60
Faludi, A., Izar, M., Saraiva, J., Bianco, H. T., Chacra, A., Bertoluci, M., Moreira, R., Turatti, L., Bertolami, A., Sulzbach, M. L., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170188 · Cited by 110
Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
Patti, A. M., Rizvi, A. A., Giglio, R. V., Stoian, A. P., Ligi, D., & Mannello, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040912 · Cited by 59
“gov identifier: NCT01107886) reported a 27% of increased of risk for HF-related hospitalizations [63]; while, in patients with T2DM and acute coronary syndrome EXAMINE trial (EXamination of cArdiovascular outcoMes with alogliptIN vs.”
BackgroundMethodCD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology
Kawakita, E., Koya, D., & Kanasaki, K. (2021) · Cancers · doi:10.3390/cancers13092191 · Cited by 69
“SAVOR-TIMI 53 [96,100] EXAMINE [97] TECOS [98] CARMELINA [99] VERIFY [101]”
Genuth, S. (2015) · Diabetes Care · doi:10.2337/dc14-0565 · Cited by 60
Koibuchi, N., Hasegawa, Y., Katayama, T., Toyama, K., Uekawa, K., Sueta, D., Kusaka, H., Ma, M., Nakagawa, T., Lin, B., et al. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0157-0 · Cited by 60
Seufert, J. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s90662 · Cited by 65
“The recent cardiovascular endpoint studies SAVOR-TIMI 53 and EXAMINE, published in 2013, displayed a neutral effect on cardiovascular outcomes for the antidiabetic dipeptidyl peptidase-4 (DPP-4) inhibitors saxagliptin and alogliptin without being able to demonstrate any cardiovascular benefit.(10,11) Currently, there…”
Xiao, C., Dash, S., Morgantini, C., Adeli, K., & Lewis, G. F. (2015) · Diabetes · doi:10.2337/db14-1706 · Cited by 60
Preiss, D., Dawed, A., Welsh, P., Heggie, A., Jones, A. G., Dekker, J., Koivula, R., Hansen, T. H., Stewart, C., Holman, R. R., et al. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12826 · Cited by 59
Sönmez, A., Yumuk, V., Haymana, C., Demirci, İ., Barçın, C., Kiyici, S. K., Güldiken, S., Örük, G., Saydam, B. Ö., Baldane, S., et al. (2019) · Obesity Facts · doi:10.1159/000496624 · Cited by 61
GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review
Mori, Y., Matsui, T., Hirano, T., & Yamagishi, S.-I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041509 · Cited by 60
“Degradation resistant GIP analog, N-AcGIP (LysPAL [37]) at 12.”
BackgroundIqbal, N., Parker, A., Frederich, R., Donovan, M., & Hirshberg, B. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-33 · Cited by 61
“It may be that further analysis of SAVOR results or the other prospective CV outcome trials with DPP-4 inhibitors [56,57] will give further clarity to the two issues raised here.”
InfluentialSelf-citationNovel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus
Sumida, Y., Seko, Y., Yoneda, M., & Japan Study Group of NAFLD (JSG‐NAFLD) (2017) · Hepatology Research · doi:10.1111/hepr.12856 · Cited by 60
Nusca, A., Tuccinardi, D., Pieralice, S., Giannone, S., Carpenito, M., Monte, L., Watanabe, M., Cavallari, I., Maddaloni, E., Ussia, G. P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670155 · Cited by 65
“Standard of Care (EXAMINE) trials, DPP4i did not appear to increase the risk of MACEs (Scirica et al., 2013; White et al., 2013).”
MethodSeidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 48
Targeting metabolic disturbance in the diabetic heart
Fuentes-Antrás, J., Picatoste, B., Ramírez, E., Egido, J., Tuñón, J., & Lorenzo, Ó. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0173-8 · Cited by 60
“DPP-4 inhibitors Higher risk of subclinical cardiac dysfunction and HF hospitalization [28,30,39,40]”
BackgroundMethodNew and emerging regulators of intestinal lipoprotein secretion
Xiao, C., Dash, S., Morgantini, C., & Lewis, G. F. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.047 · Cited by 62
“Similarly, saxagliptin did not significantly increase or decrease CVD events in patients with type 2 diabetes [63].”
BackgroundLehrke, M., Marx, N., Patel, S. D., Seck, T. L., Crowe, S., Cheng, K., von Eynatten, M., & Johansen, O. E. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.008 · Cited by 63
“No difference in the primary composite endpoint of CV death, myocardial infarction, or ischemic stroke was found in saxagliptinor placebo-treated patients.(55) An unexpected finding of this trial was an increased incidence of hospital admissions for chronic heart failure in patients receiving saxagliptin, whereas no d…”
Backgroundon behalf of the LEADER investigators, Masmiquel, L., Leiter, L. A., Vidal, J., Bain, S., Petrie, J., Franek, E., Raz, I., Comlekci, A., Jacob, S., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0341-5 · Cited by 57
“Similarly, in the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus (SAVOR)–thrombolysis in myocardial infarction (TIMI) 53 study, the prevalence of obesity (BMI ≥30 kg/m2) was 53 % [20].”
BackgroundSelf-citationRisk of fractures and diabetes medications: a nationwide cohort study
Choi, H. J., Park, C., Lee, Y., Ha, Y., Jang, S., & Shin, C. S. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3595-6 · Cited by 63
“However, recent studies reported that use of DPP4-I was not associated with fracture risk [13–15].”
BackgroundResultHeart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
Standl, E., Schnell, O., & McGuire, D. K. (2016) · Circulation Research · doi:10.1161/circresaha.116.306924 · Cited by 59
Self-citationHeart Failure: a Major Cardiovascular Complication of Diabetes Mellitus
Bahtiyar, G., Gutterman, D. D., & Lebovitz, H. E. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0809-4 · Cited by 64
Lian, Y., Xia, X.-J., Zhao, H., & Zhu, Y. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.148 · Cited by 63
Kitada, M., Ogura, Y., Monno, I., & Koya, D. (2018) · Nutrients · doi:10.3390/nu10050544 · Cited by 65
Montoya, P. A., Múñoz, Ó., Cardozo, D. M. G., García, O. M., Fernandez-Ávila, D. G., Casas, L. Á., Bohórquez, L. F., Toro, C. M. A., Carvajal, L., de Peña, D. R., et al. (2016) · Colombia medica · doi:10.25100/cm.v47i2.2207 · Cited by 97
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 69
Krittayaphong, R., & Permsuwan, U. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.08.017 · Cited by 65
Huang, J., Jia, Y., Sun, S., & Meng, L. (2020) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-020-00447-w · Cited by 66
“Our study did not detect the signals for cardiac disorders (cardiac failure, cardiac failure congestive, and myocardial infarction), which agrees with the clinical trial [46].”
BackgroundResultAnderson, S. G., Dunn, W. B., Banerjee, M., Brown, M., Broadhurst, D., Goodacre, R., Cooper, G. J. S., Kell, D. B., & Cruickshank, J. K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103217 · Cited by 68
“current treatment results in clinical trials, is that complications are not prevented by glycemic control, intensive or not [5–7], confirmed by the latest very large trials of dipeptidyl peptidase-4 (DPP-4) inhibitors [8].”
BackgroundSchnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N., Skra, J., Valensi, P., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0357-x · Cited by 59
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.013 · Cited by 59
Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema
Stone, C. A., & Brown, N. J. (2017) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2017.04.006 · Cited by 66
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 70
“3 years), preexisting CV disease or multiple risk factors, and an average baseline HbA1c of 8% [95].”
BackgroundThe heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59
“b Incidence of HF hospitalization by prevalent HF in placebo arms of CV outcomes trials of glucose-lowering drugs (pioglitazone [29, 30], lixisenatide [31, 32], liraglutide [33, 34], alogliptin [35, 36], saxagliptin [37, 38], sitagliptin [39, 40], and empagliflozin [41, 42]) and the relative incidence rate ratio for H…”
BackgroundInfluentialColagiuri, S., Matthews, D. R., Leiter, L. A., Chan, S. P., Sesti, G., & Marre, M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.028 · Cited by 63
Self-citationProença, C., Ribeiro, D., Freitas, M., Carvalho, F. D., & Fernandes, E. G. R. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1872483 · Cited by 66
“Unexpectedly, several previous meta-analyses have studied the association of the use of DPP-4 inhibitors and hospitalizations for heart failure (Scirica et al. 2013; Monami, Dicembrini, and Mannucci 2014; Kundu et al. 2016; Li et al. 2016; Elgendy et al. 2017; Rehman et al. 2017; Verma et al. 2017;…”
ResultDiabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
The Year in Cardiology 2013: cardiovascular disease prevention
Gielen, S., & Landmesser, U. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht551 · Cited by 71
Cardiovascular safety profile of currently available diabetic drugs.
Azimova, K., Juan, Z. T. S., & Mukherjee, D. (2014) · PubMed Central · Cited by 82
Tubulointerstitial disease in diabetic nephropathy
Tonolo, G., & Cherchi, S. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s37883 · Cited by 69
“Studies have suggested possible direct renoprotective effects of DPP-4 inhibition that may go beyond its glucose-lowering potential.(72,73) Another important factor that contributes to tubulointerstitial injury is chronic hypoxia.”
Optimal therapy of type 2 diabetes: a controversial challenge
Dardano, A., Penno, G., Prato, S. D., & Miccoli, R. (2014) · Aging · doi:10.18632/aging.100646 · Cited by 69
Khunti, K., Bellary, S., Karamat, M. A., Patel, K., Patel, V., Jones, A., Gray, J., Shepherd, P., Hanif, W., & the South Asian Health Foundation (2017) · Diabetic Medicine · doi:10.1111/dme.13103 · Cited by 58
Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes
Xu, J., & Rajaratnam, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0499-5 · Cited by 59
“However, in the pre-specified secondary end-points analysis, heart failure hospitalization was more common in the saxagliptin group (3·5 vs 2·8%, HR 1·27, 95% CI 1·07–1·51, p = 0·007) [60], although this increased risk subsided by 10–11 months after randomization [61].”
BackgroundIncorporating Site-less Clinical Trials Into Drug Development: A Framework for Action
Hirsch, I. B., Martinez, J., Dorsey, E. R., Finken, G., Fleming, A., Gropp, C., Home, P., Kaufer, D., & Papapetropoulos, S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.018 · Cited by 60
Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials
Caruso, I., Cignarelli, A., & Giorgino, F. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.07.004 · Cited by 58
The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure
Bhatt, D. L., Verma, S., & Braunwald, E. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.10.008 · Cited by 58
Self-citationSachinidis, A., Nikolic, D., Stoian, A. P., Papanas, N., Tarar, O., Rizvi, A. A., & Rizzo, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154343 · Cited by 58
Type 2 diabetes and cardiovascular disease: what next?
Joseph, J. J., & Golden, S. H. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000044 · Cited by 57
Alfredsson, J., Green, J. B., Stevens, S. R., Reed, S. D., Armstrong, P. W., Angelyn Bethel, M., Engel, S. S., McGuire, D. K., Van de Werf, F., Hramiak, I., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13377 · Cited by 59
“The observation that sitagliptin vs placebo had no significant effect on major adverse CV outcomes is consistent with findings from trials of other DPP-4 inhibitors, including saxagliptin and alogliptin.(28,29) However, no detailed sex-specific data have been published from those trials.”
ResultSelf-citationDPP4 Activity, Hyperinsulinemia, and Atherosclerosis
Love, K. M., & Liu, Z. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab078 · Cited by 63
Murase, H., Kuno, A., Miki, T., Tanno, M., Yano, T., Kouzu, H., Ishikawa, S., Tobisawa, T., Ogasawara, M., Nishizawa, K., et al. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0264-6 · Cited by 59
On the potential of acarbose to reduce cardiovascular disease
Standl, E., Theodorakis, M. J., Erbach, M., Schnell, O., & Tuomilehto, J. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-81 · Cited by 66
“representatives of the innovative class of dipeptidylpeptidase-4 (DPP-4) inhibitors have recently failed to demonstrate significant CV outcome benefits in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR-TIMI 53) and the Examination of Cardiovascular Outcomes with Alog…”
BackgroundDPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
Bae, E. J. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0813-x · Cited by 62
“A 4-year study of saxagliptin has shown that the type 2 diabetes patients with a history of cardiovascular events who have received saxagliptin treatment were hospitalized for heart failure in a higher rate compared to the placebo group (Scirica et al. 2013).”
BackgroundPathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy
Alonso, N., Moliner, P., & Mauricio, D. (2017) · Advances in experimental medicine and biology · doi:10.1007/5584_2017_105 · Cited by 59
Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano
Gómez‐Huelgas, R., Peralta, F. G., Rodríguez‐Mañas, L., Formiga, F., Puig‐Domingo, M., Bravo, J. J. M., Miranda, C., & Ena, J. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2017.12.003 · Cited by 70
Zhang, J., Chen, Q., Zhong, J., Liu, C., Zheng, B., & Gong, Q. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01050 · Cited by 62
“However, these studies found no significant improvements in a range of safety endpoints for cardiovascular diseases (2, 3).”
BackgroundThe role of Dipeptidyl Peptidase‐4 in cutaneous disease
Patel, P. M., Jones, V., Kridin, K., & Amber, K. T. (2020) · Experimental Dermatology · doi:10.1111/exd.14228 · Cited by 61
“[11] Scirica BM, Bhatt DL, Braunwald E, et al.”
BackgroundLiu, D., Jin, B., Chen, W., & Yun, P. (2019) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-019-0293-y · Cited by 56
“…patients assigned to control group (n) Gantz2017 [7] RCT 2012–2017 2092 2100 Green2015 [8] RCT 2008–2015 7332 7339 Park2015 [9] OS 2007–2011 1866 5179 Scirica2013 [10] RCT 2010–2011 8280 8212 Shih2016 [11] OS 2009–2013 53,208 53,208 Wang2015 [12] OS 2009–2011 547 2735 White2013 [13] RCT…”
Greene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., Sattar, N., McGuire, D. K., Januzzi, J. L., Stockbridge, N., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.047 · Cited by 56
“SAVOR–TIMI 53 (2013) (16,28) DPP-4 inhibitors 16,492 Yes Not described 12.”
MethodInfluentialSelf-citationJarolim, P., White, W. B., Cannon, C. P., Gao, Q., & Morrow, D. A. (2018) · Diabetes Care · doi:10.2337/dc18-0109 · Cited by 56
Paul, S. K., Klein, K., Maggs, D., & Best, J. H. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0178-3 · Cited by 55
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials
Bailey, C. J., & Marx, N. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13492 · Cited by 62
“51).(57) This compares with a non-significant increase with alogliptin in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial (3.”
ResultScheen, A. J. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.10.003 · Cited by 63
Bouchi, R., Kondo, T., Ohta, Y., Goto, A., Tanaka, D., Satoh, H., Yabe, D., Nishimura, R., Harada, N., Kamiya, H., et al. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13960 · Cited by 60
Metabolic abnormalities of the heart in type II diabetes
Amaral, N., & Okonko, D. O. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115580936 · Cited by 63
Penno, G., Garofolo, M., & Prato, S. D. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.01.001 · Cited by 57
Hirano, T., & Mori, Y. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12446 · Cited by 55
de Boer, S. A., Heerspink, H. J. L., Juárez‐Orozco, L. E., van Roon, A. M., Kamphuisen, P. W., Smit, A. J., Slart, R. H. J. A., Lefrandt, J. D., & Mulder, D. J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12925 · Cited by 59
“Nevertheless, DPP-4 enzyme inhibition might also result in unfavourable CV effects; an increased rate of hospitalization for heart failure was observed in one CV outcome trial.(6)”
BackgroundSharma, A., Mentz, R. J., Granger, B. B., Heitner, J. F., Cooper, L. B., Banerjee, D., Green, C. L., Majumdar, M. D., Eapen, Z., Hudson, L., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.01.007 · Cited by 52
Birkeland, K. I., Bodegård, J., Banerjee, A., Kim, D. J., Norhammar, A., Eriksson, J. W., Thuresson, M., Okami, S., Ha, K. H., Kossack, N., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14189 · Cited by 58
Repurposing Antidiabetic Drugs for Cardiovascular Disease
Schubert, M., Hansen, S., Leefmann, J., & Guan, K. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.568632 · Cited by 61
Marston, N., Patel, P. N., Kamanu, F., Nordio, F., Melloni, G. E. M., Roselli, C., Gurmu, Y., Weng, L.-C. C., Bonaca, M. P., Giugliano, R. P., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.051927 · Cited by 58
Self-citationDo Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?
Clifton, P. M. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.10.009 · Cited by 56
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
Fujiyoshi, A., Kohsaka, S., Hata, J., Hara, M., Kai, H., Masuda, D., Miyamatsu, N., Nishio, Y., Ogura, M., Sata, M., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0285 · Cited by 61
Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus
Hirshberg, B., Parker, A., Edelberg, H., Donovan, M., & Iqbal, N. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2502 · Cited by 55
“Recently reported results from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial provide additional information regarding the overall benefit–risk ratio with saxagliptin as well as the risk of AEs of special interest [40].”
BackgroundResultInfluentialSelf-citationNeumiller, J. J. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.013 · Cited by 59
Approach to diabetes management in patients with CVD
Lathief, S., & Inzucchi, S. E. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.05.005 · Cited by 58
“[47] Scirica BM, Bhatt DL, Braunwald E, et al.”
BackgroundGlucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Giorgino, F., Home, P. D., & Tuomilehto, J. (2016) · Diabetes Care · doi:10.2337/dcs15-3023 · Cited by 54
Lee, G., Oh, S.-W., Hwang, S.-S., Yoon, J. W., Kang, S., Joh, H.-K., Kwon, H., Kim, J., & Park, D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177646 · Cited by 53
Liraglutide and Glycaemic Outcomes in the LEADER Trial
Zinman, B., Nauck, M. A., Bosch‐Traberg, H., Frimer‐Larsen, H., Ørsted, D. D., & Buse, J. B. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0524-z · Cited by 60
Future perspectives of the pharmacological management of diabetic dyslipidemia
Patti, A. M., Giglio, R. V., Παπάνας, Ν., Rizzo, M., & Rizvi, A. A. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567328 · Cited by 58
Cardiometabolic effects of a new class of antidiabetic agents
Desouza, C. V., Gupta, N., & Patel, A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.02.016 · Cited by 54
Cheng, D., Fei, Y., Liu, Y., Li, J., Chen, Y., Wang, X., & Wang, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111543 · Cited by 59
Mogensen, U. M., Andersson, C., Fosbøl, E. L., Schramm, T. K., Vaag, A. A., Scheller, N. M., Torp-Pedersen, C. T., Gislason, G., & Køber, L. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12314 · Cited by 59
“In the randomized trial, Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR TIMI-53) [13], the DPP-4 inhibitor saxagliptin had neutral effects on CV events when added to standard care in 16 492 high-risk patients followed up for a median of 2.1 years.”
BackgroundMethodResultInfluentialTherapeutic strategies utilizing SDF-1α in ischaemic cardiomyopathy
Ziff, O. J., Bromage, D. I., Yellon, D. M., & Davidson, S. M. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx203 · Cited by 60
“007).(63) A subsequent sub-study found HF hospitalization to be highest in patients with elevated natriuretic peptides, previous HF or CKD.”
BackgroundMetformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes
Crowley, M. J., Williams, J. W., Kosinski, A. S., D’Alessio, D. A., & Buse, J. B. (2017) · Diabetes Care · doi:10.2337/dc17-1528 · Cited by 54
Bretón‐Romero, R., Weisbrod, R. M., Feng, B., Holbrook, M., Ko, D., Stathos, M. M., Zhang, J., Fetterman, J. L., & Hamburg, N. M. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009379 · Cited by 54
Gutierrez, J. A., Scirica, B. M., Bonaca, M. P., Steg, P. G., Mosenzon, O., Hirshberg, B., Im, K., Raz, I., Braunwald, E., & Bhatt, D. L. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.09.014 · Cited by 55
Self-citationOxidized LDL upregulates macrophage DPP4 expression via TLR4/TRIF/CD36 pathways
Rao, X., Zhao, S. W., Braunstein, Z., Mao, H., Razavi, M. A., Duan, L., Wei, Y., Toomey, A. C., Rajagopalan, S., & Zhong, J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.065 · Cited by 56
“However, given the relative neutrality of recent trials with DPP4 catalytic inhibitors [21,22], the role of DPP4 has been questioned.”
Documento de abordaje integral de la diabetes tipo 2
Reyes‐García, R., Moreno, Ó., Pérez, C. T., Fernández‐García, D., Bellido, V., Casares, M. L. D. L. T., Rozas-Moreno, P., Fernández‐García, J. C., Martínez, A. M., Escalada, J., et al. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.10.010 · Cited by 59
SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
Ali, A., Bain, S. C., Hicks, D., Jones, P. N., Patel, D., Evans, M., Fernando, K., James, J., Milne, N., Viljoen, A., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0657-8 · Cited by 62
Stephens, J. W., Brown, K. E., & Min, T. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13942 · Cited by 61
“Infarction (TIMI) 53 trial, saxagliptin was associated with significantly less worsening and more improvement in microalbumin levels at 1 year, at 2 years, and by the end of treatment.(104) The reduction in”
O’Fee, K., Deych, E., Ciani, O., & Brown, D. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.5726 · Cited by 59
Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 50
Self-citationInsulin plus incretin: A glucose-lowering strategy for type 2-diabetes
Ahrén, B. (2014) · World J Diabetes · doi:10.4239/wjd.v5.i1.40 · Cited by 51
Ghosh, R. K., Bandyopadhyay, D., Hajra, A., Biswas, M., & Gupta, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.134 · Cited by 56
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
Avogaro, A., Fadini, G. P., Sesti, G., Bonora, E., & Prato, S. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0431-4 · Cited by 55
“We now have the results of 6 of such trials: 3 assessing safety of dipeptidyl peptidase (DPP) 4 inhibitors [37–39], 2 testing the safety of a glucagon-like peptide-1 receptor agonist (GLP1-RA) [40, 41], and 1 of an inhibitor of the sodium-glucose co-transporter (SGLT)-2 [42].”
Background
Metadata
- Authors
- Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenzon, O., McGuire, D. K., Ray, K. K., Leiter, L. A., & Raz, I.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- AstraZeneca (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Hadassah Medical Center (IL)
- St George's, University of London (GB)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1317-1326
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2064130493
- Cited by
- 3,470
- References
- 38
- Citations by year
- 2026: 82 · 2025: 137 · 2024: 129 · 2023: 157 · 2022: 182 · 2021: 233 · 2020: 322 · 2019: 324 · 2018: 365 · 2017: 392 · 2016: 422 · 2015: 337 · 2014: 320 · 2013: 57
- FWCI
- 297.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion)
- Hispana (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Griffith Research Online (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- saxagliptin, type 2 diabetes, DPP-4 inhibitors, cardiovascular safety, cardiovascular outcomes, myocardial infarction, ischemic stroke, cardiovascular mortality, heart failure hospitalization, pancreatitis, non-inferiority, antidiabetic drugs, cardiovascular risk stratification, glycemic control
- MeSH terms
- Adamantane, Aged, Aged, 80 and over, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Dipeptides, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Pancreatitis, Kaplan-Meier Estimate, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.